Literature DB >> 15705787

Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site.

Keiji Nogami1, Qian Zhou, Hironao Wakabayashi, Philip J Fay.   

Abstract

Thrombin-catalyzed proteolysis at Arg372 of factor VIII is essential for procofactor activation. However, hemophilia A patients with the missense mutation Arg372 to His possess a mild to moderate phenotype yet show no detectable cleavage at this bond. To evaluate this discrepancy, we prepared and stably expressed a recombinant, B-domainless factor VIII mutant (R372H) that possessed approximately 1% the specific activity of wild type. Cleavage at R372H by thrombin occurred with an approximately 80-fold decreased rate compared with wild type. N-terminal sequence analysis of the derived A2 subunit confirmed that cleavage occurred at the His372-Ser373 bond. Factor VIII R372H was activated slowly, attained lower activity levels, and exhibited an apparent reduced inactivation rate compared with factor VIII wild type. These observations were attributed to a reduced cleavage rate at His372. Factor Xa generation assays showed similar Michaelis-Menten constant (K(m), apparent) values for thrombin-catalyzed activation for either factor VIII form, but suggested an approximately 70-fold reduced maximum velocity (V(max)) for factor VIII R372H. However, prolonged reaction with thrombin yielded similar activity and stability values for the mutant and wild-type factor VIIIa forms. These results indicate a markedly reduced rate of cleavage following substitution at the P(1)Arg, and this property likely reflects the severity of the hemophilia A phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705787      PMCID: PMC1895030          DOI: 10.1182/blood-2004-10-3939

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

1.  Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity.

Authors:  Hironao Wakabayashi; Jan Freas; Qian Zhou; Philip J Fay
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

2.  Immunologic studies of antihemophilic factor (AHF, factor VIII): cross-reacting material in a genetic variant of hemophilia A.

Authors:  L W Hoyer; R T Breckenridge
Journal:  Blood       Date:  1968-12       Impact factor: 22.113

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue.

Authors:  D L Higgins; J A Shafer
Journal:  J Biol Chem       Date:  1981-12-10       Impact factor: 5.157

5.  Expression of active human factor VIII from recombinant DNA clones.

Authors:  W I Wood; D J Capon; C C Simonsen; D L Eaton; J Gitschier; B Keyt; P H Seeburg; D H Smith; P Hollingshead; K L Wion; E Delwart; E G Tuddenham; G A Vehar; R M Lawn
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

6.  An immunoradiometric assay for procoagulant factor VIII antigen: results in haemophilia, von Willebrand's disease and fetal plasma and serum.

Authors:  I R Peake; A L Bloom; J C Giddings; C A Ludlam
Journal:  Br J Haematol       Date:  1979-06       Impact factor: 6.998

7.  Immunoradiometric measurement of the factor VIII procoagulant antigen.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

8.  Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.

Authors:  D A Lane; C Southan; H Ireland; E Thompson; M Kehl; A Henschen
Journal:  Br J Haematol       Date:  1983-04       Impact factor: 6.998

9.  Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside.

Authors:  L T Mimms; G Zampighi; Y Nozaki; C Tanford; J A Reynolds
Journal:  Biochemistry       Date:  1981-02-17       Impact factor: 3.162

10.  The effect of thrombin on human factor VIII. Cleavage of the factor VIII procoagulant protein during activation.

Authors:  L W Hoyer; N C Trabold
Journal:  J Lab Clin Med       Date:  1981-01
View more
  12 in total

1.  A factor VIII-derived peptide enables von Willebrand factor (VWF)-binding of artificial platelet nanoconstructs without interfering with VWF-adhesion of natural platelets.

Authors:  Hassan Haji-Valizadeh; Christa L Modery-Pawlowski; Anirban Sen Gupta
Journal:  Nanoscale       Date:  2014-05-07       Impact factor: 7.790

2.  Hemophilia A: different phenotypes may be explained by multiple and variable effects of the causative mutation in the F8 gene.

Authors:  Giancarlo Castaman
Journal:  Haematologica       Date:  2018-02       Impact factor: 9.941

3.  Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of Factor VIIIa.

Authors:  Fatbardha Varfaj; Julie Neuberg; P Vincent Jenkins; Hironao Wakabayashi; Philip J Fay
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

4.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

5.  Sequences flanking Arg336 in factor VIIIa modulate factor Xa-catalyzed cleavage rates at this site and cofactor function.

Authors:  Jennifer P DeAngelis; Hironao Wakabayashi; Philip J Fay
Journal:  J Biol Chem       Date:  2012-03-12       Impact factor: 5.157

6.  The role of P4-P3' residues flanking Arg336 in facilitating activated protein C-catalyzed cleavage and inactivation of factor VIIIa.

Authors:  Jennifer P DeAngelis; Fatbardha Varfaj; Hironao Wakabayashi; Philip J Fay
Journal:  Thromb Res       Date:  2011-04-05       Impact factor: 3.944

Review 7.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

8.  Cleavage at Arg-1689 influences heavy chain cleavages during thrombin-catalyzed activation of factor VIII.

Authors:  Jennifer L Newell; Philip J Fay
Journal:  J Biol Chem       Date:  2009-02-24       Impact factor: 5.157

9.  Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.

Authors:  Irving Donadon; John H McVey; Isabella Garagiola; Alessio Branchini; Mimosa Mortarino; Flora Peyvandi; Francesco Bernardi; Mirko Pinotti
Journal:  Haematologica       Date:  2017-11-23       Impact factor: 9.941

10.  Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII.

Authors:  Bredon Crawford; Margareth C Ozelo; Kenichi Ogiwara; James Ahlin; Silvia Albanez; Carol Hegadorn; Lori Harpell; Christine Hough; David Lillicrap
Journal:  Mol Ther Methods Clin Dev       Date:  2015-11-18       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.